Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Type 1 Diabetes
NCT02057211Phase 2Terminated
- Sponsor
- Akademiska sjukhuset
- Start
- Apr 2014
- Primary completion
- Nov 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous mesenchymal stem cells in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Akademiska sjukhuset. Primary endpoint: Change in C-peptide Area Under the Curve at 2 years. Started Apr 2014; status: terminated.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02057211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057211.